SG10201403896XA - Method for predicting efficacy of drugs in a patient - Google Patents
Method for predicting efficacy of drugs in a patientInfo
- Publication number
- SG10201403896XA SG10201403896XA SG10201403896XA SG10201403896XA SG10201403896XA SG 10201403896X A SG10201403896X A SG 10201403896XA SG 10201403896X A SG10201403896X A SG 10201403896XA SG 10201403896X A SG10201403896X A SG 10201403896XA SG 10201403896X A SG10201403896X A SG 10201403896XA
- Authority
- SG
- Singapore
- Prior art keywords
- drugs
- patient
- predicting efficacy
- predicting
- efficacy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22379809P | 2009-07-08 | 2009-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201403896XA true SG10201403896XA (en) | 2014-10-30 |
Family
ID=42790891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201403896XA SG10201403896XA (en) | 2009-07-08 | 2010-07-06 | Method for predicting efficacy of drugs in a patient |
| SG2012001384A SG177571A1 (en) | 2009-07-08 | 2010-07-06 | Method for predicting efficacy of drugs in a patient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012001384A SG177571A1 (en) | 2009-07-08 | 2010-07-06 | Method for predicting efficacy of drugs in a patient |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10095829B2 (zh) |
| EP (1) | EP2452281B1 (zh) |
| JP (1) | JP5773998B2 (zh) |
| CN (1) | CN102473202B (zh) |
| AU (1) | AU2010270227B2 (zh) |
| CA (1) | CA2767659C (zh) |
| DK (1) | DK2452281T3 (zh) |
| EA (1) | EA021945B1 (zh) |
| ES (1) | ES2763899T3 (zh) |
| IL (1) | IL217338A (zh) |
| NZ (1) | NZ597655A (zh) |
| SG (2) | SG10201403896XA (zh) |
| WO (1) | WO2011003911A1 (zh) |
| ZA (1) | ZA201200872B (zh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| DK3147373T3 (da) | 2010-07-27 | 2019-08-12 | Genomic Health Inc | Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer |
| WO2012019191A2 (en) * | 2010-08-06 | 2012-02-09 | Cardiomems, Inc. | Systems and methods for using physiological information |
| SG10201605210PA (en) | 2012-01-31 | 2016-08-30 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| RU2509808C1 (ru) * | 2012-10-30 | 2014-03-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53 |
| US10709341B2 (en) | 2012-11-21 | 2020-07-14 | St. Jude Medical Luxembourg Holdings II S.a.r.l. | Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment |
| US10262112B2 (en) * | 2013-02-04 | 2019-04-16 | Precera Bioscience, Inc. | Prescription decision support system and method using comprehensive multiplex drug monitoring |
| WO2014137705A1 (en) * | 2013-03-05 | 2014-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine |
| US9198908B2 (en) | 2013-03-15 | 2015-12-01 | St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) | Methods for the treatment of cardiovascular conditions |
| RU2528247C2 (ru) * | 2013-05-07 | 2014-09-10 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления |
| RU2666921C2 (ru) * | 2013-06-20 | 2018-09-13 | Тайхо Фармасьютикал Ко., Лтд. | СПОСОБ ПРЕДСКАЗАНИЯ ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ИНГИБИТОРА PI3K/AKT/mTOR НА ОСНОВАНИИ ЭКСПРЕССИИ PHLDA1 ИЛИ PIK3C2B |
| ES2832886T3 (es) * | 2013-08-19 | 2021-06-11 | Cipherome Inc | Método y sistema para seleccionar un fármaco sobre la base de la información del daño de proteína individual para prevenir los efectos secundarios de un fármaco |
| EP2881472A1 (en) * | 2013-12-09 | 2015-06-10 | Université Pierre et Marie Curie (Paris 6) | A method of predicting a response to an anti-tumor treatment |
| AU2015249513A1 (en) * | 2014-04-24 | 2016-10-06 | Pfizer Inc. | Cancer treatment |
| EP3766986B1 (en) * | 2014-12-31 | 2022-06-01 | Guardant Health, Inc. | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results |
| EP3261008B1 (en) | 2015-02-17 | 2021-09-08 | Cipherome, Inc. | Method for selecting anticancer agent based on protein damage information of individual to prevent anticancer agent side effects |
| WO2018078142A1 (en) * | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of fluorouracil (5-fu) in colorectal cancer (crc) therapy |
| CN113621706B (zh) * | 2017-06-22 | 2024-05-10 | 北海康成（北京）医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| RU2670656C9 (ru) * | 2017-08-30 | 2018-12-12 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования роста опухоли в эксперименте |
| CN108053887A (zh) * | 2017-11-02 | 2018-05-18 | 杭州英放生物科技有限公司 | 一种实体瘤疗效评估方法、电子设备、存储介质、系统 |
| WO2019168426A1 (ru) * | 2018-03-01 | 2019-09-06 | Общество С Ограниченной Ответственностью "Онкобокс" | Способ и система для оценки клинической эффективности таргетных лекарственных средств |
| US11424011B2 (en) * | 2018-12-10 | 2022-08-23 | International Business Machines Corporation | Analyzing knowledge graphs with unbounded insight generation |
| US20200222538A1 (en) * | 2019-01-15 | 2020-07-16 | International Business Machines Corporation | Automated techniques for identifying optimal combinations of drugs |
| CN110241215B (zh) * | 2019-07-03 | 2020-05-19 | 上海润安医学科技有限公司 | 一种用于检测甲状腺结节良恶性相关基因变异的引物及试剂盒 |
| US11373281B1 (en) * | 2021-02-23 | 2022-06-28 | Qualcomm Incorporated | Techniques for anchor frame switching |
| JP2024509887A (ja) * | 2021-03-09 | 2024-03-05 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｐ３００分解剤および神経芽細胞腫におけるその使用 |
| KR102421466B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
| WO2023109876A1 (en) * | 2021-12-16 | 2023-06-22 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909906A (pt) * | 1998-04-03 | 2000-12-26 | Triangle Pharmaceuticals Inc | Sistemas, métodos e produtos de programa de computador para guiar a seleção de regimes de tratamento terapêutico |
| JP2006271385A (ja) * | 2001-03-14 | 2006-10-12 | Dna Chip Research Inc | 大腸癌の予測方法 |
| JP4222835B2 (ja) | 2001-03-14 | 2009-02-12 | 株式会社Ｄｎａチップ研究所 | 癌の予測方法 |
| US20060275747A1 (en) | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
| ATE458003T1 (de) * | 2001-12-07 | 2010-03-15 | Novartis Vaccines & Diagnostic | Bei prostatakrebs hochreguliertes endogenes retrovirus |
| JP2005519610A (ja) * | 2002-03-13 | 2005-07-07 | エフ．ホフマン−ラ ロシュ アーゲー | 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法 |
| JP2005038256A (ja) * | 2003-07-16 | 2005-02-10 | Jgs:Kk | 有効因子情報選択装置、有効因子情報選択方法、プログラム、および、記録媒体 |
| US8000982B2 (en) * | 2004-02-17 | 2011-08-16 | Body Bio, Inc. | Network and methods for integrating individualized clinical test results and nutritional treatment |
| US7693857B2 (en) * | 2005-11-17 | 2010-04-06 | International Business Machines Corporation | Clinical genomics merged repository and partial episode support with support abstract and semantic meaning preserving data sniffers |
| DK2508621T3 (en) * | 2005-11-29 | 2015-01-12 | Childrens Hosp Medical Center | Optimization and individualization of drug selection and dosage |
| US20070198653A1 (en) * | 2005-12-30 | 2007-08-23 | Kurt Jarnagin | Systems and methods for remote computer-based analysis of user-provided chemogenomic data |
| US7788259B2 (en) * | 2006-07-21 | 2010-08-31 | Microsoft Corporation | Locating, viewing and interacting with information sources |
| US20080118576A1 (en) * | 2006-08-28 | 2008-05-22 | Dan Theodorescu | Prediction of an agent's or agents' activity across different cells and tissue types |
-
2010
- 2010-07-06 US US13/382,585 patent/US10095829B2/en active Active
- 2010-07-06 CA CA2767659A patent/CA2767659C/en active Active
- 2010-07-06 SG SG10201403896XA patent/SG10201403896XA/en unknown
- 2010-07-06 CN CN201080030902.XA patent/CN102473202B/zh active Active
- 2010-07-06 WO PCT/EP2010/059648 patent/WO2011003911A1/en active Application Filing
- 2010-07-06 JP JP2012518969A patent/JP5773998B2/ja active Active
- 2010-07-06 AU AU2010270227A patent/AU2010270227B2/en active Active
- 2010-07-06 ES ES10730780T patent/ES2763899T3/es active Active
- 2010-07-06 NZ NZ597655A patent/NZ597655A/xx unknown
- 2010-07-06 EP EP10730780.3A patent/EP2452281B1/en active Active
- 2010-07-06 EA EA201200101A patent/EA021945B1/ru not_active IP Right Cessation
- 2010-07-06 SG SG2012001384A patent/SG177571A1/en unknown
- 2010-07-06 DK DK10730780.3T patent/DK2452281T3/da active
-
2012
- 2012-01-03 IL IL217338A patent/IL217338A/en active IP Right Grant
- 2012-02-06 ZA ZA2012/00872A patent/ZA201200872B/en unknown
-
2018
- 2018-09-10 US US16/125,803 patent/US20190005190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012533103A (ja) | 2012-12-20 |
| CA2767659A1 (en) | 2011-01-13 |
| CN102473202A (zh) | 2012-05-23 |
| AU2010270227B2 (en) | 2015-01-22 |
| JP5773998B2 (ja) | 2015-09-02 |
| US20120136583A1 (en) | 2012-05-31 |
| ZA201200872B (en) | 2012-10-31 |
| AU2010270227A1 (en) | 2012-02-09 |
| EA021945B1 (ru) | 2015-10-30 |
| EP2452281B1 (en) | 2019-10-02 |
| NZ597655A (en) | 2013-05-31 |
| CA2767659C (en) | 2020-10-20 |
| ES2763899T3 (es) | 2020-06-01 |
| US10095829B2 (en) | 2018-10-09 |
| WO2011003911A1 (en) | 2011-01-13 |
| SG177571A1 (en) | 2012-03-29 |
| US20190005190A1 (en) | 2019-01-03 |
| EA201200101A1 (ru) | 2012-08-30 |
| DK2452281T3 (da) | 2020-01-13 |
| EP2452281A1 (en) | 2012-05-16 |
| IL217338A0 (en) | 2012-02-29 |
| CN102473202B (zh) | 2015-11-25 |
| IL217338A (en) | 2017-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201200872B (en) | Method for predicting efficacy of drugs in a patient | |
| IL250068A0 (en) | Method and intermediates for preparing pharmaceutical substances | |
| ZA201201975B (en) | Improved device and method for delivery of a medicament | |
| IL241752A0 (en) | A method for monitoring a patient's response | |
| SG2014014732A (en) | Method for forming a tissue construct and use thereof | |
| ZA201201389B (en) | Sterilization method and appartus | |
| IL214919A0 (en) | Method for therapeutic use | |
| EP2473964A4 (en) | KIT OF MEDICAL OBSERVANCE | |
| PL2878317T3 (pl) | Sposób działania odciągacza pokarmu i odciągacz pokarmu | |
| EP2609846A4 (en) | ENCAPSULATED MEDICAL DEVICE AND METHOD OF MANUFACTURING THEREOF | |
| ZA201200069B (en) | Method for treating a patient in need of aspirin therapy | |
| ZA201109514B (en) | Method of drug delivery | |
| GB0901795D0 (en) | Medical device and method | |
| IL207251A0 (en) | Method of predicting pain medication efficacy | |
| EP2614824A4 (en) | THERAPEUTIC AGENT AGAINST PAIN | |
| EP2556471A4 (en) | METHOD AND DEVICE FOR CARRYING OUT CLINICAL TRIALS | |
| IL210428A (en) | Apadnosone dosing unit and method of use | |
| IL213955A (en) | Method for improved biological activity of pharmaceutical preparations | |
| EP2489300A4 (en) | ENCAPSED MEDICAL DEVICE AND METHOD FOR PRODUCING THE ENCAPSULATED MEDICAL DEVICE | |
| GB0903193D0 (en) | Medical device and method | |
| GB0903190D0 (en) | Medical device and method | |
| GB0903188D0 (en) | Medical device and method | |
| GB0903189D0 (en) | Medical device and method | |
| GB0903191D0 (en) | Medical device and method | |
| GB0903192D0 (en) | Medical device and method |